|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Different strategies of treatment for uterine cervical carcinoma stage ⅠB2-ⅡB显示文摘Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage ⅠB2-ⅡB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries. Thus, radical concurrent chemoradiation is the standard of care in United Sated and Canada, and neoadjuvant chemotherapy followed by radical surgery is the first line of treatment in some institutions of Europe, Asia and Latin America. Until today, there is no evidence of which strategy is better over the other. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment for women affected by uterine cervical cancer stage ⅠB2-ⅡB. | Lucas Minig María Guadalupe Patrono Nuria Romero Juan Francisco Rodríguez Moreno Jesús Garcia-Donas | 2014 | World Journal of Clinical Oncology2014，5，2： | 46 |
| 2 | Polymorphisms in base excision repair genes: Breast cancer risk and individual radiosensitivity显示文摘Breast cancer(BC) is the most common cancer among women worldwide. The aetiology and carcinogenesis of BC are not clearly defined, although genetic, hormonal, lifestyle and environmental risk factors have been established. The most common treatment for BC includes breast-conserving surgery followed by a standard radiotherapy(RT) regimen. However, radiation hypersensitivity and the occurrence of RT-induced toxicity in normal tissue may affect patients' treatment. The role of DNA repair in cancer has been extensively investigated, and an impaired DNA damage response may increase the risk of BC and individual radiosensitivity. Single nucleotide polymorphisms(SNPs) in DNA repair genes may alter protein function and modulate DNA repair efficiency, influencing the development of various cancers, including BC. SNPs in DNA repair genes have also been studied as potential predictive factors for the risk of RT-induced side effects. Here, we review the literature on the association between SNPs in base excision repair(BER) genes and BC risk. We focusedon X-ray repair cross complementing group 1(XRCC1), which plays a key role in BER, and on 8-oxoguanine DNA glycosylase 1, apurinic/apyrimidinic endonuclease 1 and poly(ADP-ribose) polymerase-1, which encode three important BER enzymes that interact with XRCC1. Although no association between SNPs and radiation toxicity has been validated thus far, we also report published studies on XRCC1 SNPs and variants in other BER genes and RT-induced side effects in BC patients, emphasising that large well-designed studies are needed to determine the genetic components of individual radiosensitivity. | Clarice Patrono Silvia Sterpone Antonella Testa Renata Cozzi | 2014 | World Journal of Clinical Oncology2014，5，5： | 8 |
| 3 | 选择性环氧化酶2抑制剂和传统非甾体抗炎药增加粥样血栓形成的风险吗?随机试验的荟萃分析显示文摘目的:评价选择性环氧化酶2(COX-2)抑制剂和传统的非甾体类抗炎药(NSMDs)在发生血管事件上的风险性。设计:对已发表和未发表随机试验的表格式资料进行荟萃分析,对传统 NSAIDs 的作用进行间接评估。资料来源:资料分别来源于 Medline 和 Embase(1966年1月至2005年4月);食品与药品管理局记录;以及诺华、辉瑞、默克公司的资料。回顾方法:符合以下条件的随机试验入组本研究:一种选择性 COX-2抑制剂与安慰剂比较或一种选择性 COX-2抑制剂与一种传统的 NSAID之间对比;用药持续时间至少4周;包含严重血管事件方面的信息,如心肌梗死、卒中或由于血管事件死亡。各个独立研究者和药厂为本研究提供了有关随机化的病人数目、血管事件的数目以及每个随机化小组中随访的人时(Person time)等信息。结果:在与安慰剂对比的试验中,选择性COX-2抑制剂使严重血管事件发生率增加42%(1.2%/年比0.9%/年;率比1.42,95%可信区间1.13~1.78;P=0.005);不同的选择性 COX-2抑制剂之间没有显著性差异。这主要归因于心肌梗死的风险增加(0.6%/年比0.3%/年;1.86,1.33~2.59;P=0.0003),在其他血管性事件上没有明显的区别。在为时至少1年的试验中(平均2.7年),血管事件的率比是1.45(1.12~1.89;P=0.005)。总的来说,严重血管事件的发生率在选择性 COX-2抑制剂和任何传统 NSAID 之间没有差异(1.0%/年比0.9%/年;1.16,0.97~1.38;P=0.1)。然而,在选择性 COX-2抑制剂与萘普生对比的试验(1.57,1.21~2.03)和选择性COX-2抑制剂与非萘普生类 NSAIDs 相比较的试验之间(0.88,O.69~1.12),我们发现了统计学差异。与安慰剂比较血管事件的总体比率如下:萘普生0.92(0.67~1.26),布洛芬1.51(0.96~2.37),双氯芬酸1.63(1.12~2.37)。结论:选择性 COX-2抑制剂可以中等度增加血管事件的风险性,大剂量布洛芬和双氯芬酸同样具有此作用,但大剂量萘普生不明显增加血管事件的风险性。 | Patricia M Kearney Colin Baigent Jon Godwin Heather Halls Jonathan R Emberson Carlo Patrono 徐东(译) 张卓莉(校) | 2006 | 英国医学杂志中文版2006，9，5： | 4 |
| 4 | High occurrence of Helicobacter pylori in raw goat, sheep and cow milk inferred by glm M gene: A risk of food-borne infection?显示文摘 | N.C. Quaglia A. Dambrosio G. Normanno A. Parisi R. Patrono G. Ranieri A. Rella G.V. Celano | 2008 | International Journal of Food Microbiology2008，，1： | 2 |
| 5 | Vanadyl phosphate dihydrate supported on oxides for the catalytic conversion of ethane to ethylene显示文摘 | L Lisi P Patrono G Ruoppolo | 2003 | J Mol Catal A:Chemical2003，204，： | 2 |
| 6 | The coxibs,selective inhibitors of cyclooxygenase-2显示文摘 | FITZGERALD GA PATRONO C | 2001 | N Engl J Med2001，345，6： | 1 |
| 7 | Platelet-active drugs : the rela- tionships among dose, effectiveness, and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy 显示文摘 | Patrono C Coller B FitzGerald GA | 2004 | Chest2004，12，6： | 1 |
| 8 | Methanol reforming reactions over Zn/TiO2 catalysts 显示文摘 | PINZARI F PATRONO P COSTANTINO U | 2006 | Catalysis Communications2006，7，9： | 1 |
| 9 | Antiplatelet strategies显示文摘 | | 2002 | Eur Heart J2002，4，： | 1 |
| 10 | Methanol reforming reactions over Zn/TiO2 catalysts显示文摘 | PINZARI F PATRONO P CosTANTINO U | 2006 | Catalysis Communications2006，7，9： | 1 |
| 11 | Platelet-Ac- tiveDrugs: the relationships among dose, efectiveness and sideeffects: the Seventh ACCP Conference on An- tithrombotie and Thromholytic Therapy 显示文摘 | Patrono C Coller B FitzGerald GA | 2011 | Chest2011，126，3： | 1 |
| 12 | Selective oxidation of 5 -hydroxymethyl-2- furaldehyde to furan-2,5- dicarboxaldehyde by catalytic systems based on vanadyl phosphate 显示文摘 | CARL1NI C PATRONO P GALLETTI A M R | 2005 | Applied Catalysis A: General2005，289，2： | 1 |
| 13 | Platelet-active drugs : the relationships among dose, effectiveness, and side effects显示文摘 | Patrono C Coller B Dalen J E | 2001 | Chest2001，119，1： | 1 |
| 14 | Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment显示文摘 | Raffaele Landolfi Bianca Rocca Carlo Patrono | 1995 | Critical Reviews in Oncology and Hematology1995，，3： | 1 |
| 15 | Platelet active drugs:the relationships among dose, effectiveness, and side effects显示文摘 | COLLER B DALEN JE | 2001 | Chest2001，119，： | 1 |
| 16 | The coxibs, selective inhibitors of cyclooxygenase -2 显示文摘 | Fitzgerald GA Patrono C | 2001 | N Engl J Med2001，345，6： | 1 |
| 17 | Aspirin resistance:definition,mechanisms and clinical read-outs显示文摘 | Patrono C | | 0，，： | 1 |
| 18 | Platelet activation and atherothrombosis显示文摘 | Davi G Patrono C | | 0，，24： | 1 |
| 19 | Aspirin as an antiplatelet drug显示文摘 | Patrono C | 1994 | New Engl J Med1994，330，18： | 1 |
| 20 | 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC) 显示文摘 | Roffi M Patrono C Collet JP | 2016 | Eur Heart J2016，37，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员